Introduction: Accurate detection of high-grade squamous intraepithelial lesions (HSIL), particularly CIN2+ and CIN3+, in HPV-positive women is essential for cervical cancer prevention. Dual immunostaining with p16/Ki67 has been proposed as an objective triage strategy to improve diagnostic performance. Objectives: To assess the diagnostic accuracy of p16/Ki67 dual staining for detecting CIN2+ and CIN3+ in HPV-positive women through a systematic review and meta-analysis. Methods: A systematic review and meta-analysis were conducted following PRISMA-DTA guidelines. Eight observational prospective studies, including 12,810 HPV-positive women, were analyzed. Outcomes included pooled sensitivity, specificity, positive and negative likelihood ratios (LR?/LR?), diagnostic odds ratio (DOR), and area under the SROC curve (AUC). A bivariate random-effects model was used. Meta-regression and subgroup analyses assessed sources of heterogeneity. Publication bias was examined using Deeks’ test. Results: For CIN2+, pooled sensitivity was 0.83 (95% CI: 0.79–0.87; I² = 65.67%) and specificity was 0.60 (95% CI: 0.50–0.68; I² = 62.27%). The diagnostic odds ratio (DOR) was 7.0 (95% CI: 5–11), with AUC of 0.80 (95% CI: 0.76–0.83). For CIN3+, sensitivity was 0.87 (95% CI: 0.82–0.91; I² = 67.94%) and specificity was 0.55 (95% CI: 0.42–0.67; I² = 53.40%), DOR of 8.0, and AUC of 0.80. Meta-regression identified SurePath, ThinPrep, prospective design, and follow-up ?5 years as modifiers ofsensitivity and specificity (p < 0.05). Bayesian modeling estimated post-test probabilities of 41% (CIN2+) and 39% (CIN3+) after positive results. No publication bias was detected. Conclusion: Dual staining with p16/Ki67 offers acceptable diagnostic accuracy for detecting CIN2+ and CIN3+ in HPV-positive women. Standardized protocols and longer follow-up enhance its performance in clinical screening.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
